Patty Eisenhaur, former vice president of investor relations and corporate communications at Watson Pharmaceuticals, has joined IR and corporate communications consultancy EVC Group.
A biology and psychology graduate of Tufts University, Eisenhaur kick-started her career in investor relations in 1992 as an IR associate for Arris Pharmaceuticals, later joining Alza Corporation, now part of the Johnson & Johnson group, as an IR manager.
In 2001 she was hired by Watson Pharmaceuticals to serve as director of investor relations, was promoted to executive director in 2008, and to vice president a year later.
Eisenhaur will now focus on expanding the pharmaceutical and biotechnology industry practice for EVC, which operates from three offices in San Francisco, New York City and southern California.
‘EVC Group is retained by an impressive roster of clients, which is a natural fit to my background, and I’ve already enjoyed adding value to client initiatives,’ Eisenhaur declares in a press release. ‘I have joined a firm with an exceptional pharmaceutical and biotech background, both in investor relations and public relations, and it’s a pleasure to be part of such a successful team.’
‘Being able to attract Patty Eisenhaur to our practice is a major achievement for our firm,’ comments EVC’s founder and CEO Douglas Sherk. ‘Patty is extremely well regarded within the sell-side and buy-side investment communities and her depth of experience and relationships will be extremely valuable to our existing and future healthcare industry clients.
‘For the past two consecutive years, our team has had the unique distinction of winning awards for our investor relations programming on behalf of healthcare companies with sales under $500 mn. Patty adds additional depth and experience to our team as well as the perspective of having been an on-staff corporate officer at well-known companies.’
